Upcoming Phase 3 Clinical Program Will Examine Efficacy of Oral ...

Cassava Sciences Announces Completion of an Interim Safety ...

“We look forward to announcing top-line efficacy, safety and biomarker data for our 12-month Phase 3 study before the end of 2024.” The DSMB is ...

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data ...

The overall safety profile was consistent with other oral acting olanzapine options. These data were presented during the 37th Annual European ...

Bristol Myers Squibb Provides Update on the First Phase 3 ...

The induction studies include approximately 600 patients each, with responders moving on to participate in the maintenance study. Nonresponders, ...

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor ...

“The initiation of a comprehensive Phase 3 program is an important milestone in our goal to offer a highly effective oral medication that could ...

Merck to Initiate New Phase 3 Clinical Program with Lower Dose of ...

These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR/ISL). One study ...

Press Release: Tolebrutinib meets primary endpoint in HERCULES ...

Positive results from the HERCULES phase 3 study showed that tolebrutinib, Sanofi's oral brain-penetrant BTK inhibitor, met the primary endpoint of improvement ...

A Phase III, Randomized, Controlled, Global Multicenter Study to ...

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects ...

Press Release Details - NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with ...

Menarini Announces Positive Topline Data from Pivotal Phase 3 ...

Obicetrapib global, pivotal Phase 3 clinical development program consists of four studies in over 12,250 patients, three for obicetrapib ...

11 clinical trials that will shape medicine in 2023 - PMC

This is a pivotal phase 3 trial that most experts consider a huge game-changer for this field. In Alzheimer's disease, there are no disease- ...

Topline results from Boehringer's Phase III IPF Study

Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug ...

Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential ...

... will be presented as an oral presentation on Sunday, October ... discuss suzetrigine and the Phase 3 clinical trial results in acute pain.

Positive results in largest pivotal phase 3 trial of a novel antibiotic to ...

Positive results announced in largest pivotal phase 3 trial of a first-in-class oral antibiotic to treat uncomplicated gonorrhoea.

Cassava Sciences Completes Enrollment for Pivotal Phase 3 ...

The second Phase 3 trial (NCT05026177) has a 76-week treatment period; 1,125 Alzheimer's patients were randomized into this study. Top-line ...

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to ...

The phase 2/3 study used a seamless design to maximize patient recruitment during the COVID-19 pandemic, and the current phase 3 trial was ...

The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal ...

The Librexia program is the most comprehensive Factor XIa Phase 3 clinical development program ... oral factor XIa (FXIa) inhibitor ...

CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A ...

The phase 3 CLOVER study assessed the PF-06425090 vaccine for primary CDI prevention in adults. Although the primary endpoint was not met, ...

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to ...

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB) ...

Open ALS Clinical Trials - Johns Hopkins Medicine

A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral ...

A Study of Daily Oral Orforglipron (LY3502970 ... - Lilly Trials

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and ...